NEWS
General / 12. September 2024
C2 PHARMA EXPANDS OPHTHALMIC API PORTFOLIO WITH NAPHAZOLINE HYDROCHLORIDE LAUNCH
Read more
General / 15. February 2024
Ophthalmic API's Explained with C2 PHARMA
C2 PHARMA collaborates with Pharmasource to create a buyer’s guide focused on all things Ophthalmics.
Read morePress Release / 21. November 2023
C2 PHARMA Receives DMF Approval in China for Pilocarpine Nitrate
Read moreVideo / 7. November 2023
Manufacturing Chemist StandSide interview with C2 PHARMA's CEO at CPHI WW Barcelona
Read moreGeneral / 30. October 2023
Optimizing the Total Cost of Ownership by C2 PHARMA's CEO, Andrew Badrot
Featured Article in Pharmaceutical Technology’s October 2023 Ebook!
Read morepodcast / 18. October 2023
Listen to Luke Bilton speak with C2 PHARMA's Serge Tarabay about the company's rise to becoming the Global Leader in Ophthalmic APIs.
Read morePress Release / 17. October 2023
C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPhI Barcelona
Read moreVideo / 2. October 2023
Head of Quality, Tara Fitzpatrick, chats with European Senior Editor Felicity Thomas.
Read morePress Release / 27. June 2023
EDQM Grants C2 PHARMA CEP Approval for Commercial Sale of Cyclopentolate Hydrochloride
Read morePress Release / 13. June 2023
C2 PHARMA Receives Approval for Digoxin China DMF, Becoming China’s Only European Supplier of This API
Read moreGeneral / 17. March 2023
Assuring security of supply for phyto-APIs
A Manufacturing Chemist Story
Read moreGeneral / 24. November 2022
Andrew Badrot, C2 PHARMA CEO, is interviewed by MJH Life Sciences during CPhI 2022 in Frankfurt and discusses the future of the company and the CMO industry in general
Read moreGeneral / 21. November 2022
Sarah Breen, Senior Quality Manager at C2 PHARMA, shares her thoughts on supplier oversight with Susan Haigney from Pharmaceutical Technology
Read moreGeneral / 18. October 2022
C2 PHARMA Expands Ophthalmic API Portfolio with Tropicamide Launch & Multiple Regulatory Filings
Read moreGeneral / 3. August 2022
What Goes Wrong When API Quality is Compromised?
Dr. James Lawler, General Manager of C2 PHARMA shares his thoughts on API quality with Susan Haigney from Pharmaceutical Technology.
Read morePress Release / 9. November 2021
C2 PHARMA Completes Multiple Local Regulatory Filings and Expands Portfolio
Read moreGeneral / 16. April 2021
Pharmaceutical reshoring: a healthy requirement, a strategic necessity
A Manufacturing Chemist Featured Story
Read morePress Release / 23. February 2021
C2 PHARMA Completes Multiple Regulatory Filings, Expands API Portfolio
C2 PHARMA solidifies its position as a leading ophthalmic API supplier to the pharmaceutical industry
Read moreGeneral / 18. December 2020
Andrew Badrot, C2 PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic
C2 PHARMA in Pharma’s Almanac Featured Story
Read moreGeneral / 19. November 2020
Interview with Andrew Badrot, C2 PHARMA CEO
A Lëtzebuerger Merkur Featured Story
Read moreGeneral / 23. September 2020
C2 PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020
C2 PHARMA has been shortlisted in the CPhI Awards 2020 for being a key sponsor of the “Partnerships for a Better World” program.
Read moreGeneral / 31. August 2020
The Impact of Covid-19 on the Pharmaceutical Industry, a Chemanager Featured Story
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.
Read moreGeneral / 27. August 2020
Connecting industry across the globe, a Chemicals Knowledge featured story
Andrew Badrot, CEO at C2 PHARMA recently stated that the pharmaceutical industry has responded extremely well to the coronavirus pandemic but that there will be no more ‘business as usual’ in pharmaceutical manufacturing after COVID-19.
Read moreGeneral / 1. July 2020
Andrew Badrot, CEO of C2 PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic
C2 PHARMA in Pharma’s Almanac Q2 issue
Read moreGeneral / 15. May 2020
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story
The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA.
Read moreGeneral / 27. April 2020
COVID-19/Coronavirus is reshaping the pharmaceutical supply chain, a Chemical & Engineering News Featured Story
The COVID-19/Coronavirus pandemic may mark a rebalancing of where drugs are made as nations recognize a security imperative.
Read moreGeneral / 26. March 2020
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment
LUXEMBOURG, March 26, 2020 /PRNewswire/ — C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. In early March, the API was listed for its potential to reduce the symptoms of COVID-19/Coronavirus patients in combination with other anti-viral drugs based on initial research in South Korea and India.
Read moreGeneral / 19. March 2020
Andrew Badrot, CEO of C2 PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry, a Pharma's Almanac Q1 issue
Due to its nature, the pharmaceutical industry will always see M&A activity. That is not likely to change anytime soon. However, the drivers behind it do change over time, based on the trends in the market.
Read moreGeneral / 19. February 2020
C2 PHARMA highlights importance of API quality, an in-Pharma Technologist Featured Story
The quality of active pharmaceutical ingredients (APIs) is a constant source of discussion within the industry. As C2 PHARMA works to expand its API portfolio, its CEO states that there is ‘no short game’ on API quality.
Read moreGeneral / 9. January 2020
Fairness in the pharma supply chain key to success in today’s business climate, a Chemicals Knowledge featured story
Andrew Badrot, CEO of C2 PHARMA, explains that times are changing for pharma, and considers some of the factors impacting the future of the industry as we enter 2020.
Read moreGeneral / 6. December 2019
Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond
C2 PHARMA in Pharma’s Almanac Q4 issue
Read moreGeneral / 6. November 2019
Chemicals Knowledge features story on C2 Pharma's portfolio expansion
C2 PHARMA continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio.
Read moreGeneral / 4. November 2019
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development
Luxembourg, November 4, 2019 – C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio. The most recent addition enhances the previously announced Digoxin API product offer with the inclusion of a micronized grade for Digoxin from two different manufacturing sites. Multiple niche APIs and botanical extract products are also currently in technical transfer or under development, including Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
Read moreGeneral / 2. September 2019
C2 PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story
James Lawler, Head of Quality and External Supply Operations at C2 PHARMA, explains how the implementation of virtual manufacturing strategies can ensure supply chain security and the reliable delivery of high-quality active pharmaceutical ingredients (API).
Read moreGeneral / 1. July 2019
Why the industry is forming bonds with CBD
C2 PHARMA in Pharma Manufacturing Featured story
Read moreGeneral / 6. June 2019
Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge
Manufacturing Chemist cover story June 2019.
Read morePress Release / 20. March 2019
C2 PHARMA Acquires Digoxin API Portfolio from Nobilus Ent to Guarantee Long-Term Quality and Supply Chain Security
Luxembourg, March 18, 2019 – C2 PHARMA, a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has acquired the Digoxin API product portfolio of Polish company, Nobilus Ent, self-developed and inherited from Roche/Galenus Mannheim. Through the agreement, C2 PHARMA is the product owner, and Nobilus is a manufacturing partner and releasing entity for the API. Parallel manufacturing to ensure redundancy is supported by long-term partner, Laurus Labs, an India-based API manufacturer with an impeccable track record.
Read moreGeneral / 22. November 2018
FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE
05 – 06 November 2018 | London
Keynote Interview: Medicinal Cannabis: Perspectives on a Growing Market, Evolving Regulations and a Nascent Supply Chain Andrew Badrot, Founder and CEO, C2 PHARMA
Press Release / 4. October 2018
C2 PHARMA successfully completes validation campaigns for digoxin and digoxin micron
Luxembourg, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has successfully validated its manufacturing process for two APIs: digoxin and digoxin micron. Digoxin is produced at a dedicated manufacturing facility at CMO Laurus Labs, India.
Read morePress Release / 4. October 2018
C2 PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP
Luxembourg and Oslo, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) and Theracule AS are entering into a strategic partnership focused on supporting Theracule’s new drug development programs aimed at rare neurodevelopmental disorders.
Read morePress Release / 22. June 2018
C2 PHARMA buys out joint venture partner
Luxembourg & São Paulo – 22 June, 2018 – C2 PHARMA has acquired the remaining 50 % of the shares in its joint venture from PAMA Holding, the investment vehicle of the Centroflora Group in Luxembourg. CEO Andrew Badrot is now the sole shareholder of C2 PHARMA.
Read moreGeneral / 16. October 2017
CPhI 2017: C2 PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off
Luxembourg, October 16, 2017 – C2 PHARMA (Hall 11, Level 0, #B40), the company formerly known as Centroflora CMS, has announced the acquisition of German R&D synthesis services company ASM Research Chemicals in the run-up to the CPhI Worldwide exhibition in Frankfurt am Main, Germany on 24- 26 October 2017.
Read moreGeneral / 4. October 2017
Centroflora CMS changes its name to C2 PHARMA
Luxembourg, October 4, 2017 – Centroflora CMS, a Luxembourg-based venture between Swiss company CMS Pharma and Centroflora Group of Brazil, is changing its name to C2 PHARMA.
Read moreGeneral / 2. October 2017
CPhI 2017: Centroflora CMS gains CEP approvals and invests in Digoxin manufacturing facility in India
CEP approval for atropine sulfate; availability of US-DMFs for reference for both atropine sulfate and homatropine methylbromide.
Read moreGeneral / 20. September 2017
CPhI 2017: Centroflora CMS nominated for the 2017 CPhI Pharma Award for Corporate Social Responsibility
Centroflora CMS has again been nominated for the CPhI Award in the category “Excellence in Pharma: Corporate Social Responsibility” for the project “Partnership for a Better World”. This is the second year in succession that the company has been in the running for the Award.
Read moreGeneral / 5. September 2017
Centroflora CMS at CPhI 2017 in Frankfurt – booth 11.0.B40
Please join us at our booth 11.0.B40 under the Brazilian Pavillion at CPhI Frankfurt on October 24 and 26, 2017.
Read moreGeneral / 19. September 2016
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2016
Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2016 in the category Excellence in Pharma: Corporate Social Responsibility.
General / 9. September 2016
Centroflora CMS at CPhI 2016 in Barcelona – booth 3H10
Please join us at our booth 3H10 under the Brazilian Pavillion at CPhI Barcelona on October 4 and 6, 2016.
Read moreGeneral / 27. October 2015
Centroflora CMS is the winner of the 2015 CPhI Pharma Award for Excellence in Partnering & Outsourcing
We are pleased to announce that Centroflora CMS won the prestigious 2015 CPhI Pharma Awards for Excellence in Partnering & Outsourcing. Awarded by CPhI Worldwide (UBM EMEA), 16 finalists were invited to present their case during the first day of CPhI Worldwide in Madrid on October 13, 2015.
Read moreGeneral / 4. October 2015
Centroflora CMS Expands its Product and Service Offering
New service offering includes R&D leveraging a unique bioprospecting platform from the Brazilian biomes as well as contract manufacturing (CMO) services for both API and botanical extracts in Brazil.
Read moreGeneral / 21. September 2015
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2015
Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2015.
Read moreGeneral / 1. September 2015
Centroflora CMS at CPhI 2015 in Madrid
Please join us at our booth 8D20 under the Brazilian Pavillion at CPhI Madrid between October 13 and 15, 2015.
Read moreGeneral / 22. May 2015
Centroflora Group is Awarded 1st National Biodiversity Award
Centroflora Group receives the Brazilian Ministry of Environment 1st National Biodiversity Award in recognition of the Jaborandi Valorization Project.
Read moreGeneral / 16. March 2015
Firms Team Up To Sustain Natural Pilocarpine
C&EN’s Rick Mullin writes about Centroflora CMS and Centroflora’s Partnership for a Better World.
Read moreGeneral / 1. September 2014
Centroflora CMS at CPhI 2014 in Paris
Please join us at our booth 5P73 under the Brazilian Pavillion at CPhI Paris between October 7 and 9, 2014.
Read more